-
2023-508314-42-00
4
2020-02-27
Advanced stage intrahepatic biliary tract cancer (BTC)
-
2023-506832-33-00
5
2019-11-06
haemophilia A (HA) with inhibitors and haemophilia B (HB) with inhibit
-
2024-515616-47-00
5
2019-10-03
Metastatic Renal Cell Carcinoma
-
2024-514604-14-00
4
2019-09-18
Muscle-invasive bladder cancer
-
2024-519288-17-00
4
2019-04-26
High-risk Non-muscle Invasive Bladder Cancer
-
2023-509576-42-00
5
2019-02-21
Patients with resectable Non-small Cell Lung Cancer (Stage IIA to IIIB
-
2023-509602-29-00
5
2019-02-11
Patients with Limited Stage Small-Cell Lung Cancer (LS-SCLC)
-
2024-513867-19-00
5
2019-01-31
metastatic Castration-Resistant Prostate Cancer (mCRPC)
-
2023-506125-10-00
5
2018-12-24
Multiple Myeloma
-
2022-501485-22-00
5
2018-12-18
Myelodysplastic syndrome (MDS)
-
2024-516662-11-00
5
2018-11-23
Ovarian epithelial
cancer
-
2024-516905-22-00
5
2018-10-22
Multiple myeloma
-
2024-510967-41-00
5
2018-09-21
Metastatic colorectal cancer
-
2023-507657-15-00
5
2018-09-13
Ulcerative Colitis
-
2023-505341-23-00
5
2018-07-27
Non-muscle invasive bladder cancer
-
2024-512212-21-00
5
2017-11-28
Advanced hepatocellular carcinoma (HCC)
-
2023-510444-21-00
5
2017-11-24
Neuroendocrine tumours of gastroenteric or pancreatic origin
-
2023-509671-17-00
5
2017-07-12
Breast Cancer
-
2024-514841-12-00
5
2015-10-27
To determine whether the addition of palbociclib to adjuvant endocrine
-
2024-516908-42-00
4
2015-06-15
Smoldering multiple myeloma with high risk of progression to symptomat
-
2023-510082-10-00
5
2022-09-05
Advanced non-small cell lung cancer harboring the KRAS G12C mutation
-
2023-507865-24-00
5
2025-03-28
Advanced (unresectable/metastatic) melanoma
-
2024-511057-22-00
5
2024-12-04
Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia
-
2024-511557-21-00
5
2024-11-14
Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia